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The human papillomavirus (HPV) directly infects cervical keratinocytes and interferes with TLR signalling. To shed light on the
eﬀect of HPV on upstream receptors, we evaluated TLRs 1–9 gene expression in HPV-negative normal and HPV-positive pre-
malignant and malignant ex vivo cervical tissue. Quantitative real-time polymerase chain reaction was performed separately for
epithelial and stromal tissue compartments. Diﬀerences in gene expression were analyzed by the Jonckheere-Terpstra trend test
or the Student’s t-test for pairwise comparison. Laser capture microdissection revealed an increase in TLR3 and a decrease in
TLR1 mRNA levels in dysplastic and carcinoma epithelium, respectively. In the stroma, a trend of increasing TLR 1, 2, 5, 6, and
9 mRNA levels with disease severity was found. These ﬁndings implicate the involvement of TLR3 and TLR1 in early and late
cervical carcinogenesis, respectively, suggesting that stromal upregulation of TLRs may play a role in cervical disease progression.
1.Introduction
The most important role of toll-like receptors (TLRs) in host
defence is the regulation of innate and adaptive immune
responses by epithelial cells, the ﬁrst line of protection at,
for example, the respiratory, gastrointestinal tract, skin and
genitourinary mucosal sites. Present on a variety of cell
types, TLRs play an essential role in innate immune sys-
tem function by recognizing discrete exogenous pathogen-
associated molecular patterns (PAMPs) and endogenous
damage-associated molecular pattern (DAMP) ligands to
induce an innate immune response [1]. Ten functional TLRs
have been identiﬁed and characterized in humans. Among
t h e s e ,T L R s3 ,4 ,7 ,8 ,a n d9h a v eb e e nf o u n dt op l a yac r i t i c a l
role in antiviral immunity by triggering the downstream
production of interferons (IFNs) including IFN-α,I F N - β
and IFN-γ [1, 2]. IFNs are important components of the
innate immune response against invading pathogens. They
are synthesized during initial infection and evoke antiviral,
antitumour, and immune-regulatory activity which gives
protection to surrounding cells [3–5] .T h eI F Ng r o u pi ss p l i t
into two classes; Type I IFNs encompass IFN-α,- β,- κ,- δ,- ε,
-ω,a n d- τ [6], and generate antiviral activity [7], while IFN-
γ is the only type II IFN [7] and is involved in the regulation
ofimmuneandinﬂammatoryresponses[8].IFN-κisanewly
identiﬁed type I IFN and is known to have similar antiviral
properties. However, it is distinct from other type I IFNs as it
signals in a discrete autocrine, rather than paracrine manner
[9].
TLRs3,7,8,and9canbeactivatedbyviralproductssuch
as double stranded RNA [10], single stranded RNA [11], and
double stranded CpG-rich DNA [12], respectively, whereas
cell-surface TLR4 is stimulated by lipopolysaccharide (LPS)
and some viral proteins [13]. TLRs 1 and 6 recognize ba-
cterial and mycoplasma lipoproteins, respectively [14–16]
while acting in cooperation with TLR2, whereas TLR5 is
speciﬁcally stimulated by bacterial ﬂagellin [17, 18]. In
addition, damage-associated molecular patterns (DAMPS)
(which include heat shock proteins, high-mobility group2 Clinical and Developmental Immunology
Table 1: Sample size. Twenty-ﬁve frozen cervical biopsies were categorized into 3 groups; normal tissue, case IDs N1–N11; dysplastic
tissue, case IDs D1–D10; invasive carcinoma tissue, case IDs C1–C4. Laser capture microdissection was used to separate each specimen
into epithelium and stroma compartments. The HPV infection status is shown, and the speciﬁc HPV type is noted when known.
Case ID Morphological
diagnosis HPV infection status Case ID Morphological
diagnosis HPV infection status
N1 Normal Negative D3 LSIL Types 66, 82
N2 Normal Negative D4 LSIL Types 6, 66
N3 Normal Negative D5 HSIL Type 16
N4 Normal Negative D6 HSIL Type 16
N5 Normal Negative D7 HSIL Type 33
N6 Normal Negative D8 HSIL Type 16
N7 Normal Negative D9 HSII Type 16
N8 Normal Negative D10 HSII TYPe 39
N9 Normal Negative C1 Carcinoma Type 16
N10 Normal Negative C2 Carcinoma HR HPV+
N11 Normal Negative C3 Carcinoma HR HPV+
D1 LSIL Type 31 C4 Carcinoma HR HPV+
D2 LSIL Type 51
LSIL: low-grade squamous intraepithelial lesion; HR: high risk; HSIL: high-grade squamous intraepithelial lesion.
box 1 (HMGB1), uric acid crystals, hyaluronan, heparin
sulfate, messenger RNA, surfactant protein A, and various
products of the extracellular matrix such as ﬁbronectin and
ﬁbrinogen) have been suggested to activate TLRs [1].
The critical function of TLRs in innate immune func-
tioning is well studied, but, in recent years, their role in
tumour genesis and cancer progression has become an active
ﬁeldofresearch.Becauseoftheirinnateimmunitysignalling,
TLRs play an important gate keeper role in controlling the
production of proinﬂammatory cytokines and chemokines
as well as IFNs. It has recently been speculated that aberrant
TLR expression and signalling in cancer cells and the
resulting downstream cascades can directly promote tumour
progression [19]. Indeed, aberrant TLR1, 2, 3, 4, 5, 6, and 9
signalling has been implicated in a variety of human cancers
[1].
Cervical cancer is the second most common malignancy
in women worldwide with human papillomavirus (HPV)
recognized as its causative agent [20]. HPV is a double
stranded DNA virus which infects the squamous epithelium
of the uterine cervix. Most infections are cleared by the
host, but a proportion of women are unable to clear the
infection, resulting in cervical lesions. Although persistent
HPV infection is necessary, it is insuﬃcient for the devel-
opment of cervical cancer. HPV can directly inhibit the
function of TLR downstream molecules involved in the IFN
pathway [21, 22] and accumulating evidence supports an
interaction between TLRs and HPV [23–25]. TLR expression
throughoutthecourseofcervicalcarcinogenesishasnotbeen
addressed previously and requires further exploration taking
the entire tumour microenvironment into consideration. In
this regard, we have recently characterized cytokine and IFN
gene expression levels in the normal, premalignant, and
malignantepitheliumandsurroundingstromaofexvivocer-
vicaltissuebylasercapturemicroscopyandquantitativereal-
time polymerase chain reaction [26]. Compared to nor-
mal tissue, these molecules were lacking or showed low
expression in the diseased epithelium while all of them were
aberrantly increased in the tumour stroma. To provide a
completepictureofinnateimmuneresponsesinthesametis-
sue samples, here we report a comprehensive transcriptome
analysis of all upstream TLRs involved in these downstream
pathway disturbances.
2.MaterialsandMethods
2.1. Sample Preparation. Cervical biopsies were obtained
with written consent from women attending the Colposcopy
Clinic at the Thunder Bay Regional Health Sciences Centre
(TBRHSC) between November 2005 and November 2006.
The study has been approved by the local Research Ethics
Team at the TBRHSC (no. 21.05). Biopsies were snap frozen
in liquid nitrogen and immediately transferred to −80◦C.
Tissue was sectioned on a cryostat (Leica CM1850, Leica
Microsystems, Richmond Hill, ON, Canada), maintaining
tissue temperature at −20◦C using Tissue Tek embedding
medium (O.C.T. Compound, Sakura Finetek, Torrance,
Calif, USA) and sectioned. For laser capture microdissection
(LCM) analysis, 8μm-thick tissue sections were cut, adhered
to uncharged slides, and kept in −20◦Cp r i o rt oL C M
preparation. All tweezers, brushes, and surfaces were cleaned
with DEPC-treated 70% (v/v) ethanol between specimens to
reduce RNAse activity and RNA cross-contamination.
All samples collected in this study were thoroughly tested
for RNA integrity, as previously described [26, 27]. Of 110
samples, 25 had enough remaining tissue suitable for LCM
analysis. The 25 samples utilized in this study along with
their HPV infection status are listed in Table 1.I nt o t a l ,
11 of 25 samples were negative for HPV and diagnosed as
morphologically normal. Of the 14 diseased samples, 4 wereClinical and Developmental Immunology 3
diagnosed as low-grade lesions (LSIL), 6 were high-grade
lesions (HSIL), and 4 were invasive carcinomas. Importantly,
all normal tissue was negative for HPV infection, and all
diseased tissue was positive for HPV infection. Histological
diagnosis of the snap-frozen biopsy was veriﬁed before and
after LCM and correlated with the diagnosis of the biopsy
that was taken for clinical purposes.
2.2. HPV Typing and Specimen Classiﬁcation. Ten tissue
sections were cut and then taken immediately for LCM
analysis, and placed into 1.5mL microcentrifuge tubes for
DNA extraction. DNA extraction was performed using the
Qiagen QIAamp DNA micro kit (Qiagen, Mississauga, ON,
Canada) following the manufacturer’s protocol for tissue
samples. Samples were HPV genotyped using Luminex
hybridization at the National Microbiology Laboratory
(Winnipeg, B, Canada), as previously described [26]. In
addition, PCR analysis [38] and p16-based testing using
the CINtec p16 immunocytochemistry staining kit (CINtec
p16INK4a Cytology Kit; mtm laboratories, Westborough,
Mass, USA) were performed to visualize HPV infection. For
histopathological diagnosis, sections were cut and processed
forhematoxylinandeosinstaining[39]anddiagnosedbythe
same pathologist (N.E.). Tissue samples were diagnosed as
morphologically normal, low/high-grade lesion, and cervical
carcinoma tissue. For this study, samples were categorized
as HPV-negative and morphologically normal (Normal;
n = 11), HPV-positive and morphologically dysplastic
(Dysplasia; n = 10) and HPV-positive and morphologically
malignant (Carcinoma; n = 4).
2.3. RNA Extraction and Integrity Assessment. RNA was
extracted from 10 × 10μm thick tissue sections of microdis-
sected cervical cells or keratinocytes as previously described
[27]. The quality and quantity of RNA extracted from
cervicaltissuewasassessedusingtheBio-RadExperionauto-
mated electrophoresis system. RNA integrity from samples
was assessed as previously described [27].
2.4. Laser Capture Microdissection. Tissue specimens were
prepared for laser capture microdissection (LCM) using the
Arcturus Histogene Frozen Section Staining Kit, as previ-
ously described [27]. Up to ﬁve thousand captures (∼25,000
cells)ofbothepitheliumandstromaforeachtissuespecimen
were taken. Macrocaps were cleaned of unwanted debris
using CapSure pads (Arcturus) prior to being deposited into
0.5mL microfuge tubes for RNA extraction. The laser spot
size was consistently 15μm in diameter whereas the laser
power and duration ranged from 80 to 95mW and 0.65 to
0.8 millisecond duration between specimens. Images of the
excision process have been previously reported [27].
2.5. Quantitative Real-Time Polymerase Chain Reaction.
RNA isolated from samples was reverse transcribed to
complementary DNA (cDNA) using the High Capacity
cDNA Archive Kit (Applied Biosystems) according to man-
ufacturer’s directions with random hexamer primers. RNA
isolatedfrommicrodissectedsampleswasreversetranscribed
at a minimum of 0.6ng/μL (ranging from 0.6–2.8ng/μL),
depending on acquired LCM sample RNA concentration.
Complementary DNA (cDNA) was ampliﬁed using the
TaqMan PreAmp Master Mix Kit (Applied Biosystems).
Gene ampliﬁcation uniformity was assessed as previously
described [27]. Reactions were carried out according to the
quantitative real-time polymerase chain reaction (qRT-PCR)
protocol speciﬁed in the TaqMan PreAmp Master Mix Kit.
Triplicate reactions of 25μL volume were added to a 96-
optical well plate (Applied Biosystems) and incubated at
standard qRT-PCR conditions (50◦Cf o r5m i n u t e s9 5 ◦Cf o r
10 minutes and then cycled at 95◦C for 15 seconds and 60◦C
for 1 minute for 40 cycles (detection limit)). qRT-PCR was
repeated for 10% of ex vivo human samples to ensure result
reliability. Target genes were normalized to the housekeeping
gene hypoxanthine phosphoribosyltransferase1 (HPRT1), as
previous results indicate its expression is unaﬀected by HPV
infection [27]. TaqMan gene expression on demand assays
for HPRT1 and TLRs 1 through 9 were used (Applied
Biosystems). Negative controls where cDNA was omitted or
the enzyme was missing in the RT reaction were run to
monitor for contamination or nonspeciﬁc primer binding.
A positive control was included on every plate to control
for variation between runs. Relative quantiﬁcation of target
genes was performed using auto Ct and baseline settings and
a threshold of 0.20 (Applied Biosystems 7300/7500/7500 Fast
Real-Time PCR System Software).
2.6. Statistical Analysis. The diﬀerence in cycle thresholds
(ΔCT) between HPRT1 and the TLRs was calculated for each
gene in each biological sample. These values were converted
to relative expression values using 2−ΔCT [40]. Statistical
diﬀerences in gene expression levels were assessed using
the Jonckheere-Terpstra [41] test for trends when analyzing
the three tissue groups together and using the Student’s
t-test for pairwise comparison when comparing diseased
versus normal tissue. P-values for all statistical comparisons
are reported with at most two signiﬁcant digits. Statistical
signiﬁcance is stated when P ≤ 0.0 5 .A l lt e s t sa r et w o
sided if not otherwise indicated and based on the “exact”
version. Calculations were performed using Microsoft Excel
version 12 (2008) and Cytel Studio StatXact7 version 7.0.0
(2005), Cytel Software Corporation (http://www.cytel.com/)
and the SAS statistical analysis package (Version 9.1.2,
http://support.sas.com/) for statistical tests.
3. Results
3.1. Baseline TLR mRNA Levels in Normal, HPV-Negative
Ex Vivo Cervical Tissue. To deﬁne baseline mRNA levels of
TLRs in healthy cervical tissue, 11 cervical biopsies from
histologically normal, HPV-negative women were analyzed,
as shown in Table 1. Gene expression levels in the epithelium
and stroma of healthy samples are shown in Figures 1(a)
and 1(b), respectively. High levels of TLRs 1, 2, 3, and 5
mRNA were found in relation to lower levels of TLRs 4, 6,
7, and 9, with TLR 8 found at the lowest levels in normal
epithelium. Alternatively, high levels of TLRs 1, 3, 4 and 54 Clinical and Developmental Immunology
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Figure1:TLRgeneexpressioninnormal,dysplasticandcarcinomaexvivocervicaltissue.ScatterplotindicatingrelativeTLRgeneexpression
levels (logged) in normal, dysplastic and carcinoma samples in the epithelium (a) and stroma (b) compartment. Horizontal bars show
the average expression levels per group for each gene. Asterisks show signiﬁcant expression diﬀerences from normal samples according to
the Student’s t-test for pairwise comparisons. Reported average relative expression values for each gene in both tissue compartments (c),
values calculated according to 2−ΔCT∗ 1,000. Fold change values for TLRs in dysplastic and carcinoma samples (d). Signiﬁcant fold change
values according to the Student’s t-test for pairwise comparison of two types are indicated with a thick border, and genes with signiﬁcant
upregulation trends according to the Jonckheere-Terpstra test are shaded gray.
mRNA were found in relation to lower levels of TLRs 2,
6, 7 and 9, with TLR 8 again found at the lowest levels in
normal stroma. Importantly, mRNA was found for all TLRs
in healthy cervical epithelium and stroma.
3.2. TLR3 Increases in Dysplasia Epithelium While TLR1
Decreases in Carcinoma Epithelium. To characterize TLR
mRNA levels in dysplastic and carcinoma epithelium, 14
HPV-positive, diseased cervical epithelial samples were ana-
lyzed, as shown in Table 1.P r e v i o u ss t u d i e sh a v ed e m o n -
strated an interaction between TLR signalling and HPV
[25] upstream of the IFN pathway. HPV infections disrupt
cytokine expression, and the E6 and E7 oncoproteins par-
ticularly target the type I IFN pathway [42]. We previously
reported IFN-κ and IL-10 downregulation in dysplastic and
carcinoma epithelium [26]. We therefore hypothesized that
TLR mRNA expression levels would be altered due to the
presence of HPV in the epithelium, to possibly reﬂect these
downstream ﬁndings in the stroma. Using LCM to isolate
the epithelium in whole cervical biopsy sections, the current
analysisrevealedseveralsigniﬁcantdiﬀerencesinTLRmRNA
levels in HPV-positive, diseased compared to healthy, HPV-
negative epithelium (Figure 1(a)). Importantly, all epithelial
samples were positive for TLR expression (Figure 1(c)).Clinical and Developmental Immunology 5
While TLR3 levels were found to be signiﬁcantly higher
in dysplastic epithelial samples (P = 0.05, Student’s t-
test; Figure 1(d)), TLR1 levels were found to be signiﬁcantly
lower in carcinoma epithelium (P = 0.01, Student’s t-test;
Figure 1(d)). A trend analysis did not reveal any further
diﬀerencesinTLRexpressionlevelsintheepithelium.There-
fore, the most striking diﬀerences found in the epithelium
were the increased TLR3 gene expression levels in dysplastic
epithelium and the decreased TLR1 gene expression levels
in carcinoma epithelium; the latter of which corresponds
to decreased IFN-κ levels previously reported in the same
samples [26].
3.3. TLRs 1, 2, 6 as well as 5 and 9 Increase with Disease
Severity in Cervical Stroma. To characterize TLR mRNA
levels in dysplastic and carcinoma stroma, 14 HPV-positive,
diseased cervical stromal samples were analyzed, as shown
in Table 1. Previous LCM analysis of the same tissue samples
revealed increased downstream IFN mRNA levels in dysplas-
tic and carcinoma stroma [26]. TLRs are upstream elicitors
of the IFN pathways, and we therefore expected to see TLR
alterations in the stroma with cervical disease progression.
Using LCM to isolate the stroma in whole cervical biopsy
sections, the current analysis revealed several signiﬁcant
diﬀerences in TLR mRNA levels in HPV-positive, diseased
compared to healthy, HPV-negative stroma (Figure 1(b)).
Importantly, all stromal samples were positive for TLR
expression (Figure 1(c)). A trend analysis revealed increasing
expression trends with disease severity in diseased stroma
f o rT L R s1 ,2 ,6a sw e l la s5a n d9( P = 0.05, 0.001, 0.02,
0.01, and 0.04 resp., Jonckheere-Terpstra test; Figure 1(d)).
Although a trend exists, strong increases in TLR 1, 2, and 5
mRNA levels were found predominately in dysplastic stroma
(P = 0.02, 0.001 and 0.05 resp., Student’s t-test). Thus, the
most striking results found in the stroma compartment were
the increased mRNA levels for ﬁve TLRs, which coincides
with our previous reported increase in downstream IL-10,
IFN-κ,I F N - β,a n dI F N - γ in the stroma of the same samples
[26].
4. Discussion
Through the ex vivo analysis of gene expression in HPV-
negative, healthy as well as HPV-positive premalignant and
malignant cervical tissue, we report a transcriptome model
with an emphasis on tissue compartmentalization for innate
immune signalling pathways in cervical carcinogenesis. By
conducting a systematic literature survey (Table 2), we
did not ﬁnd a comparable study which elucidated the
transcriptome of TLRs (current study) and downstream
eﬀectors [26] in cervical carcinogenesis using LCM and
qPCR. Only one transcriptome study of cervical cancer
development utilizing LCM to separate tissue compartments
was found [43]. However, diﬀerential expression of TLR
or IFN expression was not discovered in that investigation
[43], likely due to low transcription levels undetectable using
microarray analysis. Other transcriptome studies (Table 2)
used primary human keratinocytes and/or cervical cancer-
derived cell lines [33, 35], whole biopsies [24, 28–31, 34, 36]
or both [25, 32, 37] or cytobrush samples [23, 44], but
to date none have analyzed the transcriptome in isolated
tissue components. Here, we found all TLRs to be expressed
ex vivo by healthy, HPV-negative cervical keratinocytes and
stroma, albeit at diﬀerent levels: mRNA for TLRs 1, 3 and
5 tended to be most abundant compared to TLRs 6 to 9,
especially TLR8, which were expressed at consistently lower
levels in either tissue compartment (Figures 1(a) and 1(b)),
while TLR 2 was expressed highest in epithelium, and TLR4
was expressed highest in stroma. These ﬁndings are partly
concordantwithapreviousinvestigation[35],whereTLRs1,
2, 3, 5, and 6 were found most abundant and TLRs 4, 7, 8,s
and 9 were expressed at lower levels in normal ectocervical
keratinocytes. Discordant TLR 6 ﬁndings may be a result
of keratinocytes being analyzed within their natural tissue
context, complete with signals from the underlying dermal
stroma, in the current analysis.
Compared to normal tissue, TLR3 was found to be
higher expressed in premalignant epithelium and TLR1 to be
expressed lower in malignant epithelium. Similar to previous
ﬁndings, [24, 25] we found a trend for TLRs 4 and 9 to
be decreased in carcinoma epithelium, although not signif-
icantly. Likewise, other TLR receptors were also decreased,
with the exception of TLR8, in the carcinoma epithelium,
but statistical signiﬁcance was not reached, possibly due to
individual diﬀerences in expression levels in ex vivo samples.
This decreasing trend in TLR expression coincides with
our previous ﬁnding that IFN-κ was abolished in diseased
epithelium, [26] and other studies have similarly revealed
lower levels of type I and II IFNs in cervical malignancy,
[30, 36, 37] although the isolation of cervical epithelium was
not performed in these studies. In contrast to low TLR levels
in carcinoma epithelium, TLRs 1, 2, 6, as well as 5 and 9
showed higher expression in premalignant and malignant
stroma compared to normal tissue. These results coincide
with previously reported increases in IL-10, IFN-κ,I F N - β,
and IFN-γ mRNA levels as well as inﬁltrating monocytes and
dendritic cells in the cervical stroma in these samples [26].
Previous investigations have also revealed elevated mRNA
level of TLRs 5 and 9 in cervical carcinoma tissue, [29, 34]
and in contrast, higher IFN-γ and IL-10 have been associated
with lower incidences of cervical dysplasia, [28]h o w e v e r
neither investigation entailed tissue microdissection to reveal
the cell types responsible.
Based on our combined gene expression ﬁndings, we
propose a disease scenario in the cervical microenvironment
(Figure 2). During early cervical carcinogenesis, when the
cervical epithelium is still undergoing diﬀerentiation, which
typically takes place parallel to the viral life cycle of
HPV, TLR3, a classical receptor eliciting antiviral responses
via IFN-regulatory factor (IRF) 3, expression increases in
dysplastic epithelium. This upregulation may be an attempt
by the infected cells to initiate immune responses against
the HPV infection [25]. The concomitant downregulation
of downstream IFN-κ in premalignant epithelium samples
could likely be attributed to interference of HPV E6 with the
IFNpathwaybyblocking IRF3[45].WealsoshowthatTLR1
wassigniﬁcantlydecreasedincarcinomaepitheliumandmay
represent the sole upstream TLR signiﬁcantly aﬀected in6 Clinical and Developmental Immunology
Table 2: Summary of literature of dysregulated innate immunity genes in cervical tissue. A systematic literature search for investigations
into TLR and IFN expression in HPV-infected cervical tissue or cell lines was performed using the following search terms in the PubMed
database: “Cervical” and “interferon gamma” (489 hits) or “interferon beta” (202 hits) or “interferon kappa” (3 hits) or “toll-like receptor”
(59 hits). Acronyms IFN-γ,- β and -κ as well as TLR in combination with “cervical” were also tried. The listed citations are articles published
up to 5 January 2011 which describe TLR and IFN gene regulation and dysregulation. Only articles published in English were considered,
and only articles relevant for our study were included in the table.
Gene Material Sample type Method Group
Normal CIN Carcinoma
15 11 13 Full biopsy qPCR Pao et al. 1995 [28]
4 12 N/S Full biopsy, HeLa qPCR, IHC de Gruijl et al. 1999 [29]
N/A N/A 52 Full biopsy qPCR, IHC Gey et al. 2003 [30]
IFN-γ 10 N/A 29 Full biopsy qPCR, IHC Alcocer-Gonz´ alez et al. 2006 [31]
6 N/A 6 Cytobrush cDNA array Manavi et al. 2007 [31]
150 198 N/A Full biopsy qPCR Scott et al. 2009 [32]
N/S N/S N/S Full biopsy, LCM qPCR DeCarlo et al. 2008 [27]
11 10 4 Full biopsy, LCM qPCR DeCarlo et al. 2010 [19]
N/A N/A N/A CK cDNA array,
qPCR Nees et al. 2001 [33]
IFN-β N/S N/S N/S Full biopsy, LCM qPCR DeCarlo et al. 2008 [27]
11 10 4 Full biopsy, LCM qPCR DeCarlo et al. 2010 [19]
N/S N/S N/S Full biopsy, LCM qPCR DeCarlo et al. 2008 [27]
IFN-κ N/S 10 N/A Full biopsy, PHFK qPCR, IHC Rincon-Orozco et al. 2009 [34]
11 10 4 Full biopsy, LCM qPCR DeCarlo et al. 2010 [19]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [25]
TLR1 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [26]
TLR2 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR, IF Hasan et al. 2007 [26]
TLR3 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [26]
TLR4 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
20 125 49 Full biopsy qPCR, IHC Yu et al. 2010 [25]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [19]
TLR5 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
9 22 24 Full biopsy qPCR Kim et al. 2008 [36]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [26]
TLR6 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [26]
TLR7 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]Clinical and Developmental Immunology 7
Table 2: Continued.
Gene Material Sample type Method Group
Normal CIN Carcinoma
34N / A CK, PHK, SiHa, CaSki, HeLa,
C33A qPCR Hasan et al. 2007 [19]
TLR8 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
34N / A Full biopsy, CK, PHK, SiHa,
CaSki, HeLa, C33A
qPCR, IF,
IHC Hasan et al. 2007 [26]
9 22 24 Full biopsy qPCR Lee et al. 2007 [37]
TLR9 12 N/A N/A CK, VK, ME180, HeLa qPCR Herbst-Kralovetz et al. 2008 [35]
65 65 N/A Cytobrush qPCR Daud et al. 2010 [24]
20 125 49 Full biopsy qPCR, IHC Yu et al. 2010 [25]
CIN, cervical intraepithelial neoplasia; CK, in vitro cervical keratinocytes; IF, immunoﬂuorescence; IHC, immunohistochemistry; LCM, laser capture
microdissection; N/A, not applicable; N/S, not stated; PHFK, primary human foreskin keratinocytes; PHK, primary human keratinocytes, anatomical origin
not speciﬁed; qPCR, quantitative real-time polymerase chain reaction; VK, vaginal keratinocytes.
IFN-β ↑TLR1
IFN-κ
IFN-γ IL-10
IFN-κ
Dysplastic
Epithelium
Stroma
↑TLR3 ↓IL-10
TLR2
TLR5
(a)
IFN-γ
Carcinoma
↓TLR1
IL-10
Epithelium
IFN-κ IFN-κ
Stroma
↑IL-10
IFN-β
(b)
Figure 2: Overall gene expression models for ex vivo dysplastic (a) and carcinoma (b) cervical epithelium and stroma. Genes presented from
the current analysis as either up or down-regulated compared to HPV-negative, normal cervical tissue. Italicized genes are based on data we
reported previously [19]. In addition to the data presented, trend analyses also revealed a signiﬁcant up-regulation of TLRs 1, 2, 5, 6, and 9
in the stroma with disease severity.
keratinocytes in late carcinogenesis. With disease severity,
the presence of HPV in the epithelium may lead to higher
expression of TLRs in diseased stroma, which can account
for the increases in IFNs previously found [26]. Altogether,
these data demonstrate that the TLR pathways are not being
induced in late carcinogenesis in the cervical epithelium,
yet the presence of HPV indirectly triggers TLR pathway
activationinthecervicalstroma,elicitingdownstreaminnate
immune responses. However, IFNs may play a direct role
in the expression levels of TLRs, as recent evidence points
towards an intriguing mechanism by which type I IFNs can
directly induce TLRs 1, 3, 5 and 7, [46] which are some of the
TLRs found to be up-regulated in diseased cervical stroma in
the present study. The presence of up-regulated responses in
the stroma and not in the epithelium may contribute to the
persistence of HPV and ultimately cultivate the progression
of the lesion.
Several mechanisms have been suggested for IFN-κ
downregulationinmalignantepithelium:(i)downregulation
of TLR9 by HPV16 E6, [25] (ii) methylation of the IFN-
κ promoter [32] and (iii) downregulation of IFN-κ by the
HPV16E6oncoprotein[47].Thepresentﬁndingssuggestyet
another potential underlying mechanism which is linked to
the three-fold and statistically signiﬁcant decreased expres-
sion level of TLR1 in malignant epithelium. In contrast, the
increased TLR1 expression in malignant stroma is likely due
toincreasedmonocyteinﬁltration,implicatingDAMPSfrom
dying cancer cells as potential ligands. This notion requires
further investigation because TLR1 is usually involved in
the activation of downstream proinﬂammatory cytokines
rather than IFNs. However, recent research suggests that in
addition to the canonical TLRs 3, 4, 7, 8, and 9, the TLR2
subfamily (TLR1, 2 and 6) is associated with IFN responses
[48].8 Clinical and Developmental Immunology
HPV-associated cancers are a worldwide health concern,
and since the recently approved prophylactic vaccine against
common high-srisk HPV types is not a treatment option,
there is a great need for studies to characterize the eﬀect
of HPV on innate immune responses to advance treatment
options. Because of their wide-ranging impact upon both
innate and adaptive immunity in several disease settings,
TLRs and their signalling pathways emerge as attractive
therapeutic targets [49]. Based on our present ﬁndings using
a highly deﬁned sample size, TLRs 3 and 1 could be further
investigated for diagnostic and eventually prognostic marker
use. Although TLRs can mediate host innate immune system
signalling, overexpression of TLRs has been paradoxically
found in many tumour cases [50]. In line with our ﬁndings
in diseased cervical stroma, TLR antagonists, for example,
which act to block MyD-88, could confer therapeutic beneﬁt
in cervical cancer patients.
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